Loading
Some patients cannot have their tumour biopsied safely. Cancer cells captured from a blood sample can sometimes be grown into a model instead.
Circulating tumour cell-derived explants have been established in small cell lung cancer and reflect donor genomics and chemotherapy response, and CTC-derived organoids have been reported in prostate and breast cancer. Success rates depend on CTC counts, which are highest in exactly the aggressive diseases where biopsies are hardest. Scaling requires better capture, culture media and cryopreservation.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Patient-derived xenografts, Patient-derived organoids, Lab models that fail to predict what happens in patients, Liquid biopsy (ctDNA).
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Lab models that fail to predict what happens in patients.